Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs

Melissa C. Paoloni, Christina Mazcko, Elizabeth Fox et al. · 2010

Read Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs by Melissa C. Paoloni, Christina Mazcko, Elizabeth Fox et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0011013.txt.

Description

Melissa Paoloni, Christina Mazcko, Elizabeth Fox and co-authors published this comparative oncology study in PLOS ONE in 2010. Rapamycin blocks the mTOR growth pathway, which drives several cancers and their resistance to chemotherapy. Instead of testing doses first in people, the team used pet dogs with naturally occurring bone cancer, a close model of the childhood disease.

Dogs with appendicular osteosarcoma entered dose cohorts of three, receiving an injected formulation while researchers tracked blood levels, safety, and whether the drug hit its target in tissue. Paoloni and colleagues sought a dose that was safe, reached relevant blood concentrations, and measurably suppressed the pathway. Using companion dogs lets pediatric oncologists skip blind dose guessing, and the dogs themselves may benefit from trials their owners choose.

Catalog record

CREATORMelissa C. Paoloni, Christina Mazcko, Elizabeth Fox et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECreative Commons CC0 License
RIGHTSCC0
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011013

Browse the full library · About the Tower of Babel